1. Unmet medical needs in metastatic lung and digestive neuroendocrine neoplasms
- Author
-
Capdevila, Jaume, Bodei, Lisa, Davies, Philippa, Gorbounova, Vera, Jensen, Robert T., Knigge, Ulrich P., Krejs, Guenter J., Krenning, Eric, O'Connor, Juan Manuel, Peeters, Marc, Rindi, Guido, Salazar, Ramon, Vullierme, Marie-Pierre, Pavel, Marianne E., Arnold, R., Bartsch, D., Baudin, E., Bodei, L., Borbath, I, Capdevila, J., Caplin, M., Chen, J., Costa, F., Couvelard, A., Cwikla, J. B., Davies, P., de Herder, W. W., Falconi, M., Falkerby, J., Fazio, N., Ferone, D., Frilling, A., Garcia-Carbonero, R., Glasberg, S., Gorbunova, V, Grossman, A., Hoersch, D., Jensen, R. T., Kaltsas, G., Kloeppel, G., Knigge, U. P., Kos-Kudla, B., Krejs, G. J., Krenning, E., Kulke, M., Lamberts, S. W. J., van Dijkum, Nieveen E., O'Connor, J. M., O'Toole, D., Pape, U. F., Partelli, S., Pavel, M. E., Ramage, J., Reed, N. Simon Beatson, Rindi, G., Rinke, A., Ruszniewski, P., Sorbye, H., Sundin, A., Scoazec, J. Y., Taal, B. G., Tiensuu, J. E., Toumpanakis, C., Valle, J., Vullierme, M. P., Welin, S., Wiedenmann, B., Capdevila, J, Bodei, L, Davies, P, Gorbounova, V, Jensen, Rt, Knigge, Up, Krejs, Gj, Krenning, E, O'Connor, Jm, Peeters, M, Rindi, G, Salazar, R, Vullierme, Mp, Pavel, Me, on behalf the ENETS 2016 Munich Advisory Board, Participant, Partelli, S, Falconi, M, Erasmus MC other, Internal Medicine, ENETS 2016 Munich Advisory Board, and Dr. Heinz-Horst Deichmann Stiftung
- Subjects
Biomedical Research ,Lung Neoplasms ,Endocrinology, Diabetes and Metabolism ,Metastasi ,Lanreotide ,Digestive System Neoplasms ,Metastasis ,030218 nuclear medicine & medical imaging ,Imaging ,chemistry.chemical_compound ,EVEROLIMUS ,0302 clinical medicine ,Endocrinology ,LANREOTIDE ,Treatment options ,TUMORS ,Clinical Practice ,Neuroendocrine Tumors ,Unmet medical needs ,SURVIVAL ,ENETS 2016 Munich Advisory Board Participants ,Life Sciences & Biomedicine ,medicine.medical_specialty ,030209 endocrinology & metabolism ,SUNITINIB ,Endocrinology & Metabolism ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,Drug Development ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,Limited evidence ,Intensive care medicine ,Science & Technology ,Endocrine and Autonomic Systems ,business.industry ,Neurosciences ,1103 Clinical Sciences ,Biomarker ,Neuroendocrine neoplasm ,chemistry ,Neuroendocrine neoplasms ,Neurosciences & Neurology ,Human medicine ,Therapy ,1109 Neurosciences ,business ,Who classification ,Biomarkers - Abstract
Unmet medical needs are not infrequent in oncology, and these needs are usually of higher magnitude in rare cancers. The field of neuroendocrine neoplasms (NENs) has evolved rapidly during the last decade, and, currently, a new WHO classification is being implemented and several treatment options are available in the metastatic setting after the results of prospective phase III clinical trials. However, several questions are still unanswered, and decisions in our daily clinical practice should be made with limited evidence. In the 2016 meeting of the advisory board of the European Neuroendocrine Tumor Society (ENETS), the main unmet medical needs in the metastatic NENs setting were deeply discussed, and several proposals to try to solve them are presented in this article, including biomarkers, imaging, and therapy.
- Published
- 2019